Abstract
The effects of D-cycloserine, a partial agonist of the N-Methyl-D-Aspartate (NMDA) receptor, were assessed in a (neuroendocrine) challenge paradigm to examine NMDA systems in male healthy volunteers, using a double-blind, placebo-controlled crossover design. Oral D-cycloserine (15, 50, and 150 mg) was readily absorbed and its plasma concentration increased dose-dependently. Behavioral and hormonal responses were measured for 240 minutes after administration of the drug. D-cycloserine was well tolerated and did not induce side-effects according to the Visual Analog Scales (VAS), the Brief Psychiatric Rating Scale (BPRS) and the Adverse Events Checklist (AEC) & codes. D-cycloserine failed to elicit a neuroendocrine response as evaluated by cortisol, prolactin, and luteinizing hormone (LH) plasma levels. The present result suggests that D-cycloserine can readily be administered to healthy volunteers but that, in the dosages used, neuroendocrine secretion fails to serve as a model for testing NMDA receptor function in humans.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Berckel, B., Lipsch, C., Timp, S. et al. Behavioral and Neuroendocrine Effects of the Partial NMDA Agonist D-cycloserine in Healthy Subjects. Neuropsychopharmacol 16, 317–324 (1997). https://doi.org/10.1016/S0893-133X(96)00196-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/S0893-133X(96)00196-0
Keywords
This article is cited by
-
Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression
Translational Psychiatry (2020)
-
A Role Beyond Learning for NMDA Receptors in Reward-Based Decision-Making—a Pharmacological Study Using d-Cycloserine
Neuropsychopharmacology (2014)
-
A role for glutamate in subjective response to smoking and its action on inhibitory control
Psychopharmacology (2011)
-
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Nature Reviews Drug Discovery (2008)
-
d-Cycloserine and performance under different states of anxiety in healthy volunteers
Psychopharmacology (2007)